SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2007

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

COMMISSION FILE NUMBER: 0-26625

NOVAMED, INC.

(Exact name of registrant as specified in its charter)

Delaware 36-4116193

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

980 North Michigan Avenue, Suite 1620, Chicago, Illinois 60611

(Address of principal executive offices)

Registrant's telephone, including area code: (312) 664-4100

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer "

Accelerated filer x

Non-accelerated filer "

Indicate by check may Yes "No x_	nark whether the registrant is a she	ell company (as defined in Rule	12b-2 of the Exchange Act).
As of November 02, per share.	2, 2007, there were outstanding 24	1,492,833 shares of the registran	t's common stock, par value \$.01

NOVAMED, INC. FORM 10-Q FOR QUARTERLY PERIOD ENDED SEPTEMBER 30, 2007 INDEX

	PART OR ITEM	PAGE
Part I.	FINANCIAL STATEMENTS	3
Item 1.	Interim Condensed Consolidated Financial Statements (unaudited)	
	Condensed Consolidated Balance Sheets – September 30, 2007 and	
	December 31, 2006	3
	Condensed Consolidated Statements of Operations – Three and nine months	
	ended September 30, 2007 and 2006	4
	Condensed Consolidated Statement of Stockholders' Equity – Nine months ende	èd
	September 30, 2007	5
	Condensed Consolidated Statements of Cash Flows – Nine months ended	
	September 30, 2007 and 2006	6
	Notes to the Interim Condensed Consolidated Financial Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of	
	Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4.	Controls and Procedures	27
Part II.	OTHER INFORMATION	28
Item 1A.	Risk factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29
		- 0
Item 6.	Exhibits	29
	Signatures	30
_		
2		

Part I. FINANCIAL INFORMATION

Item 1. Interim Condensed Consolidated Financial Statements (unaudited)

NOVAMED, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except per share data)

A CODITO	•	tember 30, 2007 naudited)	Ι	December 31, 2006
ASSETS				
Current assets:	φ	6.061	ф	2.742
Cash and cash equivalents	\$	6,961	\$	2,743
Accounts receivable, net of allowances of \$30,918 and \$32,282,		20.270		17.070
respectively		20,278		17,278
Notes and amounts due from related parties		505		505
Inventory		2,609		2,187
Prepaid expenses and deposits		1,671		1,361
Current tax assets		1,379		569
Total current assets		33,403		24,643
Property and equipment, net		15,918		15,066
Intangible assets, net		151,771		119,828
Noncurrent deferred tax assets, net		2,907		1.010
Other assets, net	¢	1,724	ф	1,010
Total assets	\$	205,723	\$	160,547
LIADII ITIES AND STOCKHOLDEDS) EQUITY				
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:				
Accounts payable	\$	6,920	\$	6,525
Accounts payable Accrued expenses and income taxes payable	Ф	5,598	Ф	6,505
Current maturities of long-term debt		1,255		1,373
Total current liabilities		13,773		14,403
Long-term debt, net of current maturities		28,838		61,227
Convertible subordinated debt, net of debt issuance costs		72,708		01,227
Other long-term liabilities		674		269
Deferred income taxes		- 074		2,236
Minority interests		15,414		14,296
Commitments and contingencies		13,414		14,290
Stockholders' equity:				
Series E Junior Participating Preferred Stock, \$0.01 par value, 1,912,000				
shares authorized, none outstanding at September 30, 2007 and December				
31, 2006, respectively		_		
Common stock, \$0.01 par value, 81,761,465 shares authorized, 29,314,936				
and 28,533,676 shares issued at September 30, 2007 and December 31,				
2006, respectively		292		285
Additional paid-in-capital		91,772		89,653
Accumulated deficit		(6,778)		(11,656)
Accumulated other comprehensive loss		(310)		(254)
recommended office comprehensive 1000		(10,660)		(9,912)
		(10,000)		(7,712)

Treasury stock, at cost, 4,822,413 and 4,713,417 shares at September 30,

2007 and December 31, 2006, respectively

Total stockholders' equity	74,316	68,116
Total liabilities and stockholders' equity	\$ 205,723 \$	160,547

The notes to the interim condensed consolidated financial statements are an integral part of these statements.

3

NOVAMED, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share data; unaudited)

	Three months ended			Nine months ended			
		September 30,			September 30,),
		2007		2006	2007		2006
Net revenue:							
Surgical facilities	\$	27,626	\$	22,249	79,615	\$	61,219
Product sales and other		5,764		5,525	17,644		17,512
Total net revenue		33,390		27,774	97,259		78,731
Operating expenses:							
Salaries, wages and benefits		10,339		8,803	30,507		25,420
Cost of sales and medical supplies		7,844		6,614	22,776		19,167
Selling, general and administrative		6,247		5,394	18,316		14,879
Depreciation and amortization		1.062					